These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17080027)

  • 1. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?
    Rückle T; Schwarz MK; Rommel C
    Nat Rev Drug Discov; 2006 Nov; 5(11):903-18. PubMed ID: 17080027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning.
    Ban K; Cooper AJ; Samuel S; Bhatti A; Patel M; Izumo S; Penninger JM; Backx PH; Oudit GY; Tsushima RG
    Circ Res; 2008 Sep; 103(6):643-53. PubMed ID: 18688045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E; Nedjar H; Bizzi A; Morin S
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.
    Hawkins PT; Stephens LR
    Science; 2007 Oct; 318(5847):64-6. PubMed ID: 17916723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
    Daikoku T; Tranguch S; Chakrabarty A; Wang D; Khabele D; Orsulic S; Morrow JD; Dubois RN; Dey SK
    Cancer Res; 2007 Jun; 67(11):5285-92. PubMed ID: 17545608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
    Ferrandi C; Ardissone V; Ferro P; Rückle T; Zaratin P; Ammannati E; Hauben E; Rommel C; Cirillo R
    J Pharmacol Exp Ther; 2007 Sep; 322(3):923-30. PubMed ID: 17526805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis.
    Jhund P; McMurray JJ
    Circulation; 2006 Jun; 113(22):2566-8. PubMed ID: 16754810
    [No Abstract]   [Full Text] [Related]  

  • 11. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.
    Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH
    Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity.
    O'Rourke AM; Wang EY; Miller A; Podar EM; Scheyhing K; Huang L; Kessler C; Gao H; Ton-Nu HT; Macdonald MT; Jones DS; Linnik MD
    J Pharmacol Exp Ther; 2008 Feb; 324(2):867-75. PubMed ID: 17993604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogens on aspirin: promising research and therapeutic applications.
    Gal-Mor O; Finlay BB
    Nat Methods; 2007 Nov; 4(11):893-4. PubMed ID: 17971779
    [No Abstract]   [Full Text] [Related]  

  • 17. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoinositide 3-kinase p110γ in immunity.
    Costa C; Martin-Conte EL; Hirsch E
    IUBMB Life; 2011 Sep; 63(9):707-13. PubMed ID: 21800408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin.
    Barberis L; Pasquali C; Bertschy-Meier D; Cuccurullo A; Costa C; Ambrogio C; Vilbois F; Chiarle R; Wymann M; Altruda F; Rommel C; Hirsch E
    Eur J Immunol; 2009 Apr; 39(4):1136-46. PubMed ID: 19291697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.